SCHOTT Pharma AG & Co. KGaA : Business case still valid after warning on 2024-25 – expected drop in share price might even lead to a buying opportunity
>Reduced volumes in mRNA project triggers warning on FY 2024-25 - Schott Pharma has just published a profit warning for FY 2024-25. Due to volume reductions by a single customer, sales in the production of syringes will be lower than originally expected. These lower volumes are related to a mRNA project with a take-or-pay contract, which means that Schott Pharma will receive compensation payments. The amount was not disclosed. The guidance for 2024-25, which has now ...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.